CCL18, CHI3L1, ANG2, IL-6 systemic levels are associated with the extent of lung damage and radiomic features in SARS-CoV-2 infection
Objective and design We aimed to identify cytokines whose concentrations are related to lung damage, radiomic features, and clinical outcomes in COVID-19 patients. Material or subjects Two hundred twenty-six patients with SARS-CoV-2 infection and chest computed tomography (CT) images were enrolled. Methods CCL18, CHI3L1/YKL-40, GAL3, ANG2, IP-10, IL-10, TNFα, IL-6, soluble gp130, soluble IL-6R were quantified in plasma samples using Luminex assays. The Mann–Whitney U test, the Kruskal–Wallis test, correlation and regression analyses were performed. Mediation analyses were used to investigate the possible causal relationships between cytokines, lung damage, and outcomes. AVIEW lung cancer screening software, pyradiomics, and XGBoost classifier were used for radiomic feature analyses. Results CCL18, CHI3L1, and ANG2 systemic levels mainly reflected the extent of lung injury. Increased levels of every cytokine, but particularly of IL-6, were associated with the three outcomes: hospitalization, mechanical ventilation, and death. Soluble IL-6R showed a slight protective effect on death. The effect of age on COVID-19 outcomes was partially mediated by cytokine levels, while CT scores considerably mediated the effect of cytokine levels on outcomes. Radiomic-feature-based models confirmed the association between lung imaging characteristics and CCL18 and CHI3L1. Conclusion Data suggest a causal link between cytokines (risk factor), lung damage (mediator), and COVID-19 outcomes..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Inflammation research - 73(2024), 4 vom: 03. Feb., Seite 515-530 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferrigno, Ilaria [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
COVID-19 |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00011-024-01852-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055314104 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055314104 | ||
| 003 | DE-627 | ||
| 005 | 20240328072108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00011-024-01852-1 |2 doi | |
| 035 | |a (DE-627)SPR055314104 | ||
| 035 | |a (SPR)s00011-024-01852-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.45 |2 bkl | ||
| 100 | 1 | |a Ferrigno, Ilaria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CCL18, CHI3L1, ANG2, IL-6 systemic levels are associated with the extent of lung damage and radiomic features in SARS-CoV-2 infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Objective and design We aimed to identify cytokines whose concentrations are related to lung damage, radiomic features, and clinical outcomes in COVID-19 patients. Material or subjects Two hundred twenty-six patients with SARS-CoV-2 infection and chest computed tomography (CT) images were enrolled. Methods CCL18, CHI3L1/YKL-40, GAL3, ANG2, IP-10, IL-10, TNFα, IL-6, soluble gp130, soluble IL-6R were quantified in plasma samples using Luminex assays. The Mann–Whitney U test, the Kruskal–Wallis test, correlation and regression analyses were performed. Mediation analyses were used to investigate the possible causal relationships between cytokines, lung damage, and outcomes. AVIEW lung cancer screening software, pyradiomics, and XGBoost classifier were used for radiomic feature analyses. Results CCL18, CHI3L1, and ANG2 systemic levels mainly reflected the extent of lung injury. Increased levels of every cytokine, but particularly of IL-6, were associated with the three outcomes: hospitalization, mechanical ventilation, and death. Soluble IL-6R showed a slight protective effect on death. The effect of age on COVID-19 outcomes was partially mediated by cytokine levels, while CT scores considerably mediated the effect of cytokine levels on outcomes. Radiomic-feature-based models confirmed the association between lung imaging characteristics and CCL18 and CHI3L1. Conclusion Data suggest a causal link between cytokines (risk factor), lung damage (mediator), and COVID-19 outcomes. | ||
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytokine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inflammation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interstitial lung disease |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Verzellesi, Laura |4 aut | |
| 700 | 1 | |a Ottone, Marta |4 aut | |
| 700 | 1 | |a Bonacini, Martina |4 aut | |
| 700 | 1 | |a Rossi, Alessandro |4 aut | |
| 700 | 1 | |a Besutti, Giulia |4 aut | |
| 700 | 1 | |a Bonelli, Efrem |4 aut | |
| 700 | 1 | |a Colla, Rossana |4 aut | |
| 700 | 1 | |a Facciolongo, Nicola |4 aut | |
| 700 | 1 | |a Teopompi, Elisabetta |4 aut | |
| 700 | 1 | |a Massari, Marco |4 aut | |
| 700 | 1 | |a Mancuso, Pamela |4 aut | |
| 700 | 1 | |a Ferrari, Anna Maria |4 aut | |
| 700 | 1 | |a Pattacini, Pierpaolo |4 aut | |
| 700 | 1 | |a Trojani, Valeria |4 aut | |
| 700 | 1 | |a Bertolini, Marco |4 aut | |
| 700 | 1 | |a Botti, Andrea |4 aut | |
| 700 | 1 | |a Zerbini, Alessandro |4 aut | |
| 700 | 1 | |a Giorgi Rossi, Paolo |4 aut | |
| 700 | 1 | |a Iori, Mauro |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |4 aut | |
| 700 | 1 | |a Croci, Stefania |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammation research |d Springer International Publishing, 1969 |g 73(2024), 4 vom: 03. Feb., Seite 515-530 |w (DE-627)SPR000002968 |w (DE-600)1459194-7 |x 1420-908X |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2024 |g number:4 |g day:03 |g month:02 |g pages:515-530 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00011-024-01852-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.45 |q VZ |
| 951 | |a AR | ||
| 952 | |d 73 |j 2024 |e 4 |b 03 |c 02 |h 515-530 | ||